Problems of Germline Therapy
By Anne McLaren and Jonathan Ewbank,
Nature
| 04. 16. 1998
Vol. 392, April 16, 1998
Sir-You recently published a full-page
report of a Californian symposium on germline gene therapy,
and a leading article, without a single mention of preimplantation
genetic diagnosis.
If a couple are at risk of having a child with a serious genetic
disease, it is now possible for them to have their embryos screened
at the eight-cell stage, after in vitro fertilization, to ensure
that only unaffected embryos are transferred to the uterus.
Only in the very rare cases where both partners are sufferers
from a recessive condition that allows survival to reproductive
age, such as cystic fibrosis, will no unaffected embryos be
generated. As 10-20 embryos could be produced from a single
egg recovery, it would not be difficult also to avoid the birth
of carriers if that was desired.
Most couples would surely prefer to avoid the transfer of
affected embryos, rather than seeking to tamper with their DNA
at such an early stage, with possibly unpredictable consequences.
Leroy Hood, chair of molecular biotechnology at the University
of Washington, said: "We are using exactly the...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
By Antonio Regalado, MIT Technology Review | 10.31.2025
A West Coast biotech entrepreneur says he’s secured $30 million to form a public-benefit company to study how to safely create genetically edited babies, marking the largest known investment into the taboo technology.
The new company, called Preventive, is...